MCID: LRY044
MIFTS: 60

Larynx Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Larynx Cancer

MalaCards integrated aliases for Larynx Cancer:

Name: Larynx Cancer 12 15
Laryngeal Carcinoma 12 77 54 56 15
Laryngeal Cancer 54 38 56
Carcinoma of Larynx 12 74
Laryngeal Neoplasm 17 74
Malignant Neoplasm of Larynx 74
Laryngeal Neoplasms 45
Cancer, Laryngeal 41
Cancer of Larynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2596 DOID:2600
KEGG 38 H00055
ICD9CM 36 161 161.9
MeSH 45 D007822
NCIt 51 C4855 C7484
SNOMED-CT 69 93859007
ICD10 34 C32 C32.9

Summaries for Larynx Cancer

Disease Ontology : 12 A larynx cancer that has material basis in epithelial cells.

MalaCards based summary : Larynx Cancer, also known as laryngeal carcinoma, is related to laryngeal squamous cell carcinoma and verrucous carcinoma. An important gene associated with Larynx Cancer is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Magnesium Sulfate and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and skin, and related phenotypes are Reduced mammosphere formation and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance

Wikipedia : 77 Laryngeal cancer are mostly squamous cell carcinomas, reflecting their origin from the skin of the... more...

Related Diseases for Larynx Cancer

Diseases in the Larynx Cancer family:

Larynx Carcinoma in Situ

Diseases related to Larynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 laryngeal squamous cell carcinoma 31.0 CCND1 CDKN2A EGFR GSTM3 GSTT1 MIR21
2 verrucous carcinoma 30.3 CCND1 CDKN2A TP53
3 asbestosis 30.1 GSTM1 GSTP1 GSTT1
4 in situ carcinoma 30.1 CDKN2A EGFR TP53
5 small cell carcinoma 29.9 CDKN2A EGFR PTEN TP53
6 inverted papilloma 29.9 CCND1 CDKN2A TP53
7 malignant peritoneal mesothelioma 29.9 CDKN2A EGFR
8 papilloma 29.8 CCND1 CDKN2A PTEN TP53
9 basaloid squamous cell carcinoma 29.7 CDKN2A EGFR TP53
10 adenoid cystic carcinoma 29.7 CCND1 PTEN SERPINB5 TP53
11 recurrent respiratory papillomatosis 29.7 EGFR TP53
12 oropharynx cancer 29.5 CCND1 CDKN2A EGFR TP53
13 lynch syndrome 29.3 CCND1 CDKN2A EGFR GSTM1 TP53
14 adenocarcinoma 29.3 CCND1 CDKN2A EGFR PTEN TP53
15 squamous cell carcinoma 28.8 CCND1 CD44 CDKN2A EGFR GSTP1 NME1
16 thyroid cancer 28.5 CCND1 EGFR GSTT1 PTEN SERPINB5 TERT
17 nasopharyngeal carcinoma 28.5 CCND1 CDKN2A EGFR GSTM1 NME1 TERT
18 pancreatic cancer 28.4 CCND1 CD44 CDKN2A DLEU2 EGFR MIR21
19 squamous cell carcinoma, head and neck 28.2 CCND1 CD44 CDKN2A EGFR FAM3D-AS1 GSTM1
20 esophageal cancer 28.0 CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
21 cervical cancer 28.0 CCND1 CD44 CDKN2A GSTM1 GSTP1 GSTT1
22 ovarian cancer 27.8 CCND1 CD44 EGFR GSTP1 MIR21 NME1
23 lung cancer 27.7 CCND1 CD44 CDKN2A EGFR GSTM1 GSTP1
24 breast cancer 27.5 CCND1 CD44 CTSD EGFR GSTP1 MIR21
25 laryngeal cancer, childhood 12.1
26 supraglottic laryngeal cancer 11.5
27 laryngeal mucoepidermoid carcinoma 11.2
28 laryngeal adenoid cystic carcinoma 11.2
29 laryngeal small cell carcinoma 11.2
30 larynx sarcoma 11.1
31 hearing loss, noise-induced 10.5 GSTM1 GSTT1
32 drug-induced hepatitis 10.4 GSTM1 GSTT1 NAT2
33 sister chromatid exchange, frequency of 10.4 GSTM1 GSTT1 XRCC1
34 diffuse gastric cancer 10.4 GSTM1 GSTP1 GSTT1
35 breast papillomatosis 10.4 CCND1 CDKN2A
36 senile cataract 10.4 GSTM1 GSTT1 XRCC1
37 tonsil squamous cell carcinoma 10.3 CCND1 CDKN2A
38 bladder squamous cell carcinoma 10.3 CDKN2A TP53
39 gastric adenosquamous carcinoma 10.3 CD44 CDKN2A TP53
40 keratinizing squamous cell carcinoma 10.3 CDKN2A TP53
41 xeroderma pigmentosum, complementation group d 10.3 GSTM1 GSTP1 GSTT1 XRCC1
42 ovarian clear cell carcinoma 10.3 CD44 PTEN TP53
43 skin carcinoma in situ 10.2 CCND1 CDKN2A
44 spitz nevus 10.2 CDKN2A TP53
45 sporadic breast cancer 10.2 PTEN TP53 XRCC1
46 acute lymphocytic leukemia 10.2 CDKN2A GSTM1 GSTT1 TP53
47 synchronous bilateral breast carcinoma 10.2 CCND1 PTEN TP53
48 basal cell carcinoma 10.2 GSTM1 GSTM3 GSTT1 TP53
49 skin melanoma 10.2 CDKN2A NME1 TP53
50 brain ependymoma 10.2 EGFR TP53

Comorbidity relations with Larynx Cancer via Phenotypic Disease Network (PDN):


Bronchitis Deficiency Anemia
Pharynx Cancer Protein-Energy Malnutrition
Respiratory Failure Supraglottis Cancer
Swallowing Disorders

Graphical network of the top 20 diseases related to Larynx Cancer:



Diseases related to Larynx Cancer

Symptoms & Phenotypes for Larynx Cancer

GenomeRNAi Phenotypes related to Larynx Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.56 CCND1 CD44 EGFR GSTM1 GSTM3 NME1
2 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CD44 CTSD EGFR GSTM1 PTEN
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CDKN2A PTEN SERPINB5 TERT TP53 XRCC1
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CCND1 CDKN2A PTEN SERPINB5 TERT TP53

MGI Mouse Phenotypes related to Larynx Cancer:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.23 CCND1 CD44 CDKN2A CTSD EGFR ENG
2 digestive/alimentary MP:0005381 10.15 CCND1 CD44 CDKN2A CTSD EGFR ENG
3 mortality/aging MP:0010768 10.15 CCND1 CD44 CDKN2A CTSD EGFR ENG
4 endocrine/exocrine gland MP:0005379 10.13 CCND1 CD44 CDKN2A CTSD EGFR NME1
5 hematopoietic system MP:0005397 10.13 CCND1 CD44 CDKN2A CTSD EGFR ENG
6 integument MP:0010771 10.06 CCND1 CD44 CDKN2A CTSD EGFR ENG
7 nervous system MP:0003631 10 CCND1 CD44 CDKN2A CTSD EGFR ENG
8 neoplasm MP:0002006 9.97 CCND1 CD44 CDKN2A EGFR NME1 PTEN
9 normal MP:0002873 9.81 CCND1 CD44 EGFR ENG PTEN SERPINB5
10 pigmentation MP:0001186 9.35 CD44 CDKN2A EGFR PTEN TP53
11 respiratory system MP:0005388 9.23 CCND1 CD44 CDKN2A EGFR ENG PTEN

Drugs & Therapeutics for Larynx Cancer

Drugs for Larynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
2
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
3
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
4
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
5
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
6
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
7 Pharmaceutical Solutions Phase 4,Phase 1,Early Phase 1,Not Applicable
8 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
9 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
10 Anesthetics Phase 4,Phase 3,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
15 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
17 Cyclooxygenase Inhibitors Phase 4,Phase 1,Phase 2
18 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
19 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
20 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
21 Tocolytic Agents Phase 4
22 Anti-Arrhythmia Agents Phase 4
23 Calcium, Dietary Phase 4,Phase 3,Phase 2
24 calcium channel blockers Phase 4
25 Hormones Phase 4,Phase 2,Phase 3,Phase 1
26 Anticonvulsants Phase 4
27 Dopamine Uptake Inhibitors Phase 4,Phase 2
28 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
30 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
31 Dopamine Agents Phase 4,Phase 2
32 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
33 Antidepressive Agents, Second-Generation Phase 4,Phase 2
34 Central Nervous System Stimulants Phase 4,Phase 3,Not Applicable
35 Nicotinic Agonists Phase 4,Not Applicable
36 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Antipyretics Phase 4,Phase 2
38 Fibrinolytic Agents Phase 4,Phase 2
39 Omega 3 Fatty Acid Phase 4,Phase 2
40 Platelet Aggregation Inhibitors Phase 4,Phase 2
41
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
42
Cisplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
43
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
44
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
45
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
46
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
47
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
48
Ethanol Approved Phase 3 64-17-5 702
49
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
50
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657

Interventional clinical trials:

(show top 50) (show all 421)
# Name Status NCT ID Phase Drugs
1 Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal Completed NCT03461328 Phase 4 Magnesium Sulphate
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 ASCEND: A Study of Cardiovascular Events iN Diabetes Active, not recruiting NCT00135226 Phase 4 Aspirin;Omega-3 Ethyl Esters;Placebo Aspirin;Placebo Omega-3 Ethyl Esters
5 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
6 the Comparison of Voice Quality in Early Laryngeal Cancer Between Surgery and Radiotherapy Unknown status NCT00497588 Phase 3
7 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
8 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
9 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
10 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer Unknown status NCT00047008 Phase 3 cisplatin
11 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
12 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx Completed NCT00002496 Phase 3 chemotherapy;cisplatin;fluorouracil
13 Randomized Trial of ARCON in Larynx Cancer Completed NCT00147732 Phase 3
14 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
15 Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx Completed NCT00002839 Phase 3 cisplatin;fluorouracil
16 Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Completed NCT00467948 Phase 3 cefazolin
17 Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Completed NCT00359645 Phase 3
18 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
19 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
20 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
21 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
22 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
23 Radiation Therapy in Treating Patients With Stage II Cancer of the Vocal Cord Completed NCT00002727 Phase 3
24 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
25 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
26 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
27 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
28 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
29 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
30 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
31 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
32 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
33 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
34 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
35 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
36 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
37 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
38 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
39 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
40 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
41 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
42 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
43 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
44 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
45 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
46 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
47 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
48 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
49 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
50 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil

Search NIH Clinical Center for Larynx Cancer

Cochrane evidence based reviews: laryngeal neoplasms

Genetic Tests for Larynx Cancer

Anatomical Context for Larynx Cancer

MalaCards organs/tissues related to Larynx Cancer:

42
Lung, Breast, Skin, Lymph Node, Brain, Liver, Thyroid

Publications for Larynx Cancer

Articles related to Larynx Cancer:

(show top 50) (show all 1252)
# Title Authors Year
1
Detection of laryngeal carcinoma in the U.S. elderly population with gastroesophageal reflux disease. ( 30681216 )
2019
2
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. ( 30884136 )
2019
3
Does Socioeconomic Status Affect Stage at Presentation for Larynx Cancer in Canada's Universal Health Care System? ( 30200820 )
2019
4
Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. ( 30476965 )
2019
5
Improving decision making in larynx cancer by developing a decision aid: A mixed methods approach. ( 30663068 )
2019
6
Volumetric modulated arc therapy with robust optimization for larynx cancer. ( 30824150 )
2019
7
Phase 1 Fractional Dose-Escalation Study of Equipotent Stereotactic Radiation Therapy Regimens for Early-Stage Glottic Larynx Cancer. ( 30880269 )
2019
8
Failed larynx preservation and survival in patients with advanced larynx cancer. ( 31036417 )
2019
9
Nuclear expression of onco-suppressors nm23-H1 and maspin are associated with lower recurrence rate in laryngeal carcinoma. ( 30683471 )
2019
10
Tumor budding in laryngeal carcinoma. ( 30706852 )
2019
11
Presentation of second primary cancers in young laryngeal carcinoma patients. ( 30712430 )
2019
12
Radiotherapy in advanced glottic laryngeal carcinoma in a patient with Wegener's granulomatosis: how much radiation dose is needed? ( 30774363 )
2019
13
Clinical Utility of Pretreatment and 3-Month 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Standardized Uptake Value in Predicting and Assessing Recurrence in T3-T4 Laryngeal Carcinoma Treated With Definitive Radiation. ( 30808209 )
2019
14
β-Arrestin-1 expression and epithelial-to-mesenchymal transition in laryngeal carcinoma. ( 30854928 )
2019
15
The prognostic value of preoperative derived neutrophil-to-lymphocyte ratio in patients undergoing total laryngectomy with laryngeal carcinoma. ( 30882257 )
2019
16
Aspernolide A Inhibits the Proliferation of Human Laryngeal Carcinoma Cells through the Mitochondrial Apoptotic and STAT3 Signaling Pathways. ( 30893785 )
2019
17
Pepsin promotes IL-8 signaling-induced epithelial-mesenchymal transition in laryngeal carcinoma. ( 30936780 )
2019
18
Clinical significance of miRNA-195 expression in patients with laryngeal carcinoma. ( 30941987 )
2019
19
The prognostic value of sex hormone receptors expression in laryngeal carcinoma. ( 30947969 )
2019
20
Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy. ( 30950440 )
2019
21
Second primary malignancies in patients with radiotherapy-treated laryngeal carcinoma - A commentary. ( 30950441 )
2019
22
DGCR5 promotes cancer stem cell-like properties of radioresistant laryngeal carcinoma cells by sponging miR-506 via Wnt pathway. ( 30980388 )
2019
23
Value of patient-reported symptoms in the follow up of patients potentially cured of laryngeal carcinoma. ( 31006407 )
2019
24
Association of SNPs in the OBFC1 gene and laryngeal carcinoma in Chinese Han male population. ( 31016429 )
2019
25
Oncological results of salvage laryngectomy in patients with laryngeal carcinoma. ( 31030804 )
2019
26
Laser transoral microsurgery in treatment of early laryngeal carcinoma. ( 31053965 )
2019
27
The rising rate of nonsmokers among laryngeal carcinoma patients: Are we facing a new disease? ( 31090946 )
2019
28
Comparative p16IKN4A Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis. ( 30275203 )
2018
29
Laryngeal Tuberculosis Mimicking Laryngeal Carcinoma on 18F-FDG PET/CT Imaging. ( 29889030 )
2018
30
Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. ( 28685830 )
2018
31
Development and external validation of a risk-prediction model to predict 5-year overall survival in advanced larynx cancer. ( 29114897 )
2018
32
Characterizing an Ultra-High-Risk Subset of Patients With Hypopharynx and Larynx Cancer: The Power of Lymph Node Burden. ( 29192300 )
2018
33
Effect of rural and urban geography on larynx cancer incidence and survival. ( 29238975 )
2018
34
Salvage Surgery after Radiation Failure in T1/T2 Larynx Cancer: Outcomes following Total versus Conservation Surgery. ( 29292665 )
2018
35
Quality of life in patients with larynx cancer in Latin America: Comparison between laryngectomy and organ preservation protocols. ( 29554402 )
2018
36
Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. ( 29598944 )
2018
37
Impact of HPV Status on the Prognostic Potential of the AJCC Staging System for Larynx Cancer. ( 29611770 )
2018
38
Epidemiological features of cancers of the oral cavity, oropharynx, hypopharynx and larynx cancer in Réunion Island. ( 29673737 )
2018
39
Decision making in advanced larynx cancer: An evidenced based review. ( 30409301 )
2018
40
From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer. ( 30409302 )
2018
41
Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies. ( 30409316 )
2018
42
Comet assay is not useful to predict normal tissue response after radiochemotherapy in cervical and larynx cancer patients. ( 30786692 )
2018
43
Lemierre Syndrome as a Complication of Laryngeal Carcinoma. ( 29849275 )
2018
44
Beclin1 enhances cisplatin-induced apoptosis via Bcl-2-modulated autophagy in laryngeal carcinoma cells Hep-2. ( 29322787 )
2018
45
Feasibility of Salvage Selective Neck Dissection after Primary Irradiation of Pharyngeal and Laryngeal Carcinoma. ( 29428959 )
2018
46
NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma. ( 29433451 )
2018
47
Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells. ( 29503530 )
2018
48
Variation in prognosis of early laryngeal carcinoma after different types of cordectomy with transoral laser microsurgery. ( 29504443 )
2018
49
TIMP-3 Increases the Chemosensitivity of Laryngeal Carcinoma to Cisplatin via Facilitating Mitochondria-Dependent Apoptosis. ( 29523219 )
2018
50
The value of whole-body contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of patients with laryngeal carcinoma. ( 29533345 )
2018

Variations for Larynx Cancer

Cosmic variations for Larynx Cancer:

9 (show top 50) (show all 322)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6927812 ZFHX3 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.4946C>T p.S1649F 16:72797736-72797736 0
2 COSM45571 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.593A>G p.E198G 17:7674938-7674938 0
3 COSM10714 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.473G>T p.R158L 17:7675139-7675139 0
4 COSM11066 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>T p.H193L 17:7674953-7674953 0
5 COSM11245 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.430C>T p.Q144* 17:7675182-7675182 0
6 COSM10779 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>T p.R273L 17:7673802-7673802 0
7 COSM10905 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.451C>T p.P151S 17:7675161-7675161 0
8 COSM43690 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.592G>A p.E198K 17:7674939-7674939 0
9 COSM10888 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.378C>A p.Y126* 17:7675234-7675234 0
10 COSM6549 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.743G>T p.R248L 17:7674220-7674220 0
11 COSM10659 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
12 COSM10893 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.824G>A p.C275Y 17:7673796-7673796 0
13 COSM44475 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.871A>T p.K291* 17:7673749-7673749 0
14 COSM10813 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.394A>G p.K132E 17:7675218-7675218 0
15 COSM11462 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.388C>G p.L130V 17:7675224-7675224 0
16 COSM6906 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.672+1G>A p.? 17:7674858-7674858 0
17 COSM44219 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.405C>G p.C135W 17:7675207-7675207 0
18 COSM44067 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.721T>A p.S241T 17:7674242-7674242 0
19 COSM11305 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.809T>C p.F270S 17:7673811-7673811 0
20 COSM11658 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>T p.K319* 17:7673573-7673573 0
21 COSM44071 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.955A>G p.K319E 17:7673573-7673573 0
22 COSM44352 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.850A>C p.T284P 17:7673770-7673770 0
23 COSM10889 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.536A>G p.H179R 17:7675076-7675076 0
24 COSM10758 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
25 COSM10660 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 0
26 COSM10742 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.578A>G p.H193R 17:7674953-7674953 0
27 COSM10777 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.715A>G p.N239D 17:7674248-7674248 0
28 COSM44456 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.668C>A p.P223H 17:7674863-7674863 0
29 COSM43949 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.401T>G p.F134C 17:7675211-7675211 0
30 COSM10645 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.527G>T p.C176F 17:7675085-7675085 0
31 COSM43935 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.577C>A p.H193N 17:7674954-7674954 0
32 COSM44103 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.737T>A p.M246K 17:7674226-7674226 0
33 COSM10654 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 0
34 COSM10648 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.524G>A p.R175H 17:7675088-7675088 0
35 COSM44143 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.919+1G>A p.? 17:7673700-7673700 0
36 COSM43826 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.706T>A p.Y236N 17:7674257-7674257 0
37 COSM44278 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.791T>C p.L264P 17:7673829-7673829 0
38 COSM98254 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.782+1G>A p.? 17:7674180-7674180 0
39 COSM11374 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.752T>A p.I251N 17:7674211-7674211 0
40 COSM44678 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.415A>T p.K139* 17:7675197-7675197 0
41 COSM43947 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 17:7674917-7674917 0
42 COSM45544 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.947C>T p.P316L 17:7673581-7673581 0
43 COSM11081 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 0
44 COSM10743 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.848G>C p.R283P 17:7673772-7673772 0
45 COSM43753 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 0
46 COSM44225 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 0
47 COSM43597 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.538G>T p.E180* 17:7675074-7675074 0
48 COSM44808 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.503A>C p.H168P 17:7675109-7675109 0
49 COSM11354 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.991C>T p.Q331* 17:7673537-7673537 0
50 COSM10726 TP53 upper aerodigestive tract,larynx,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 0

Expression for Larynx Cancer

Search GEO for disease gene expression data for Larynx Cancer.

Pathways for Larynx Cancer

Pathways related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.8 CCND1 CDKN2A EGFR GSTP1 PTEN TP53
2
Show member pathways
12.75 GSTM1 GSTM3 GSTP1 GSTT1 NAT2 NME1
3
Show member pathways
12.63 CCND1 CDKN2A EGFR PTEN TP53
4 12.44 CCND1 CDKN2A GSTP1 TP53 XRCC1
5 12.38 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
6 12.33 CCND1 CD44 CDKN2A EGFR MIR21 PTEN
7 12.29 CCND1 CDKN2A TERT TP53
8
Show member pathways
12.26 CCND1 CDKN2A PTEN SERPINB5 TP53
9
Show member pathways
12.23 GSTM1 GSTM3 GSTP1 GSTT1
10 12.18 CCND1 CD44 EGFR MIR21 TP53
11
Show member pathways
12.14 CCND1 EGFR PTEN TP53
12 12.1 CCND1 CDKN2A PTEN TP53
13 12.08 CCND1 EGFR PTEN TP53
14 12.07 CCND1 EGFR PTEN TP53
15
Show member pathways
11.99 CCND1 CDKN2A EGFR GSTM1 GSTM3 GSTP1
16 11.94 GSTM1 GSTM3 GSTP1 GSTT1 TP53
17 11.92 CCND1 CDKN2A PTEN TP53
18 11.89 CTSD EGFR PTEN SERPINB5 TP53
19 11.85 CD44 CDKN2A PTEN TP53
20 11.81 CCND1 PTEN TP53
21 11.79 CCND1 EGFR PTEN
22 11.76 CCND1 CDKN2A EGFR PTEN TP53
23 11.73 NME1 TERT TP53
24
Show member pathways
11.72 GSTM1 GSTP1 GSTT1
25 11.63 CCND1 EGFR TERT
26 11.62 EGFR PTEN TP53
27 11.62 CCND1 CDKN2A EGFR TP53
28 11.52 CCND1 PTEN TP53
29 11.5 CDKN2A GSTM1 GSTM3 GSTP1 GSTT1 TP53
30 11.49 CCND1 CD44 TP53
31 11.44 CCND1 CDKN2A EGFR TP53
32
Show member pathways
11.4 GSTM1 GSTP1 NAT2
33 11.17 GSTM1 GSTP1 GSTT1
34 11.07 GSTM1 GSTP1 GSTT1
35 10.84 GSTP1 GSTT1

GO Terms for Larynx Cancer

Cellular components related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 PTEN TERT TP53

Biological processes related to Larynx Cancer according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 CDKN2A MIR21 NME1 PTEN TP53
2 positive regulation of gene expression GO:0010628 9.91 CDKN2A ENG MIR21 PTEN TP53
3 negative regulation of gene expression GO:0010629 9.9 ENG MIR21 NME1 TERT
4 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.89 CD44 EGFR MIR21 PTEN
5 response to drug GO:0042493 9.83 CCND1 ENG NME1 PTEN XRCC1
6 negative regulation of apoptotic process GO:0043066 9.8 CD44 EGFR GSTP1 MIR21 PTEN TERT
7 response to organic substance GO:0010033 9.78 CCND1 PTEN XRCC1
8 positive regulation of protein phosphorylation GO:0001934 9.78 CCND1 EGFR ENG MIR21
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.76 GSTP1 MIR21 PTEN
10 regulation of protein stability GO:0031647 9.75 CDKN2A PTEN TERT
11 cellular response to drug GO:0035690 9.73 EGFR NME1 TP53
12 response to estradiol GO:0032355 9.62 CCND1 EGFR GSTP1 PTEN
13 positive regulation of superoxide anion generation GO:0032930 9.61 EGFR GSTP1
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.57 EGFR TP53
15 mitotic G1 DNA damage checkpoint GO:0031571 9.54 CCND1 TP53
16 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.52 ENG MIR21
17 xenobiotic catabolic process GO:0042178 9.49 GSTM1 GSTM3
18 nitrobenzene metabolic process GO:0018916 9.46 GSTM1 GSTM3
19 cellular detoxification of nitrogen compound GO:0070458 9.4 GSTM1 GSTM3
20 response to UV-A GO:0070141 9.37 CCND1 EGFR
21 replicative senescence GO:0090399 9.33 CDKN2A TERT TP53
22 glutathione metabolic process GO:0006749 9.26 GSTM1 GSTM3 GSTP1 GSTT1
23 glutathione derivative biosynthetic process GO:1901687 8.92 GSTM1 GSTM3 GSTP1 GSTT1

Molecular functions related to Larynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.87 EGFR ENG GSTM3 NME1 PTEN TERT
2 protein kinase binding GO:0019901 9.73 CCND1 CDKN2A EGFR GSTP1 PTEN TP53
3 glutathione binding GO:0043295 9.33 GSTM1 GSTM3 GSTP1
4 glutathione transferase activity GO:0004364 9.26 GSTM1 GSTM3 GSTP1 GSTT1
5 enzyme binding GO:0019899 9.23 CCND1 EGFR GSTM1 GSTM3 NME1 PTEN

Sources for Larynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....